These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 33847661

  • 21. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 22. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.
    Ziai D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni B, Monteil J.
    Cancer Imaging; 2013 Mar 05; 13(1):73-80. PubMed ID: 23466871
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
    Beer L, Hochmair M, Haug AR, Schwabel B, Kifjak D, Wadsak W, Fuereder T, Fabikan H, Fazekas A, Schwab S, Mayerhoefer ME, Herold C, Prosch H.
    Clin Nucl Med; 2019 Jul 05; 44(7):535-543. PubMed ID: 31021918
    [Abstract] [Full Text] [Related]

  • 25. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
    Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC.
    Eur J Nucl Med Mol Imaging; 2015 Mar 05; 42(3):386-96. PubMed ID: 25359635
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors.
    Nasir Z, Mahmood T, Adel H, Nausheen S, Hamid S, Sattar A, Manohar M.
    Cureus; 2019 Aug 18; 11(8):e5422. PubMed ID: 31632874
    [Abstract] [Full Text] [Related]

  • 28. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
    Katsuura T, Kitajima K, Fujiwara M, Terada T, Uwa N, Noguchi K, Doi H, Tamaki Y, Yoshida R, Tsuchitani T, Fujita M, Yamakado K.
    Ann Nucl Med; 2018 Aug 18; 32(7):453-462. PubMed ID: 29858797
    [Abstract] [Full Text] [Related]

  • 29. Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan.
    Kitajima K, Kaida H, Nakatani K, Ishibashi M, Morita T, Nakajo M, Tamaki Y, Minamimoto R.
    Nucl Med Commun; 2020 May 18; 41(5):443-451. PubMed ID: 32187159
    [Abstract] [Full Text] [Related]

  • 30. Early 18F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K, Nielsen D, Jensen BV, Pfeiffer P, Hendel HW.
    Acta Oncol; 2016 May 18; 55(9-10):1175-1182. PubMed ID: 27548393
    [Abstract] [Full Text] [Related]

  • 31. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.
    Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2018 Jul 18; 45(8):1289-1296. PubMed ID: 29478079
    [Abstract] [Full Text] [Related]

  • 32. Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab.
    Chen A, Mokrane FZ, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella JM, Vercellino L, Casasnovas O, Chauchet A, Delmer A, Nicolas-Virelizier E, Ghesquières H, Moles-Moreau MP, Schmitt A, Dulery R, Bouabdallah K, Borel C, Touati M, Deau-Fischer B, Peyrade F, Seban RD, Manson G, Armand P, Houot R, Dercle L.
    J Nucl Med; 2020 May 18; 61(5):649-654. PubMed ID: 31628220
    [Abstract] [Full Text] [Related]

  • 33. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N.
    BMC Cancer; 2019 Oct 21; 19(1):974. PubMed ID: 31638948
    [Abstract] [Full Text] [Related]

  • 34. Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.
    Mortazavi-Jehanno N, Giraudet AL, Champion L, Lerebours F, Le Stanc E, Edeline V, Madar O, Bellet D, Pecking AP, Alberini JL.
    Eur J Nucl Med Mol Imaging; 2012 Mar 21; 39(3):450-60. PubMed ID: 22183107
    [Abstract] [Full Text] [Related]

  • 35. Measurement of changes in serum-based inflammatory indicators to monitor response to nivolumab monotherapy in advanced gastric cancer: a multicenter retrospective study.
    Inukai M, Nishi T, Matsuoka H, Matsuo K, Suzuki K, Serizawa A, Akimoto S, Nakauchi M, Tanaka T, Kikuchi K, Shibasaki S, Uyama I, Suda K.
    BMC Cancer; 2024 Sep 09; 24(1):1121. PubMed ID: 39251991
    [Abstract] [Full Text] [Related]

  • 36. Nivolumab Rechallenge After Prior Nivolumab Therapy in Advanced Gastric Cancer: A Single-Center Case Series and Literature Review.
    Tsuji K, Miyajima S, Kito Y.
    J Gastrointest Cancer; 2024 Jun 09; 55(2):956-960. PubMed ID: 38165606
    [Abstract] [Full Text] [Related]

  • 37. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
    van der Hiel B, Aalbersberg EA, van den Eertwegh AJM, de Wit-van der Veen LJ, Stokkel MPM, Lopez-Yurda M, Boellaard R, Kapiteijn EW, Hospers GAP, Aarts MJB, de Vos FYFL, Boers-Sonderen MJ, van der Veldt AAM, de Groot JWB, Haanen JBAG.
    Clin Nucl Med; 2024 Feb 01; 49(2):138-145. PubMed ID: 38113329
    [Abstract] [Full Text] [Related]

  • 38. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods.
    Ayati N, Lee ST, Zakavi SR, Cheng M, Lau WFE, Parakh S, Pathmaraj K, Scott AM.
    J Nucl Med; 2021 Jul 01; 62(7):926-933. PubMed ID: 33246978
    [Abstract] [Full Text] [Related]

  • 39. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
    Lang D, Huemer F, Rinnerthaler G, Horner A, Wass R, Brehm E, Akbari K, Granitz M, Hutarew G, Kaiser B, Greil R, Lamprecht B.
    Target Oncol; 2019 Dec 01; 14(6):707-717. PubMed ID: 31654203
    [Abstract] [Full Text] [Related]

  • 40. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma.
    Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL.
    J Nucl Med; 2017 Sep 01; 58(9):1421-1428. PubMed ID: 28360208
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.